No actionable change — the retracted study on Rolupram for noise-induced tinnitus should be disregarded entirely; it must not be cited or used to inform any clinical or research decisions.
Retraction of a tinnitus neuroinflammation study removes a potentially flawed data point from the literature and serves as a reminder to verify citation integrity in a field where preclinical animal studies are heavily relied upon.
- 01Retraction issued for a 2024 paper on Rolupram and neuroinflammation in noise-induced tinnitus mice.
- 02Original study claimed Rolupram acted via TLR4/NF-κB/NLRP3/caspase-1/IL-1β pathway.
- 03Published in International Journal of Biological Macromolecules; reason for retraction not specified in the notice.
- 04Retracted work should not be cited or built upon in future tinnitus research.
- 05Highlights ongoing concerns about research integrity in preclinical hearing science.
The 2024 article claiming Rolupram reduces neuroinflammation in noise-induced tinnitus mice via TLR4/NF-κB/NLRP3/caspase-1/IL-1β signaling has been formally retracted.
guidelinesupported- PMID
- 42481331
- DOI
- 10.1016/j.ijbiomac.2026.153433.